- Mankind Pharma rose 8.86% to ₹2,516.80 at 12:44 IST on 27 Oct 2026.
- Volume so far was 3.12× its 20-session average.
- Q2 FY27 net profit: ₹716 crore, +37.67% on a year earlier.
- Nifty Pharma was +1.90%.
Figures as of: 12:44 IST, Tuesday 27 October 2026
Mankind Pharma Ltd. (MANKIND) rose 8.86% to ₹2,516.80 at 12:44 IST on Tuesday 27 October 2026. The trading volume reached 3.12× the 20-session average. The company filed Q2 FY27 results on Monday 26 October 2026, reporting a net profit of ₹716 crore. The stock traded at ₹2,516.80 on Tuesday.
Mankind Pharma share price today
| Price (12:44 IST) | ₹2,516.80 |
| Change from the previous close (₹2,312.00) | +₹204.80 (+8.86%) |
| Day’s range | ₹2,352.10 – ₹2,518.00 |
| Volume so far | 20.3 lakh shares |
| 20-session average daily volume | 6.5 lakh shares (volume so far is 3.12× that) |
| Closing prices of the previous 4 sessions | ₹2,212.60 – ₹2,312.00 |
| 52-week range (adjusted prices) | ₹1,909.70 – ₹2,642.00 |
| Price against that range | 4.7% below the high, 31.8% above the low |
| Market value at this price | ₹1.04 lakh crore |
The share price traded between ₹2,352.10 and ₹2,518.00 during the session. Trading volume reached 20.3 lakh shares, which is 3.12× the 20-session average daily volume of 6.5 lakh shares. The current price of ₹2,516.80 is 4.7% below the 52-week high of ₹2,642.00.
What has been announced
| When (IST) | Filing |
|---|---|
| Mon 26 Oct, 3:28 pm | Announcement under Regulation 30 (LODR)-Investor Presentation |
| Mon 26 Oct, 3:26 pm | Announcement under Regulation 30 (LODR)-Press Release / Media Release |
| Mon 26 Oct, 3:24 pm | Announcement under Regulation 30 (LODR)-Scheme of Arrangement |
| Mon 26 Oct, 3:21 pm | Announcement under Regulation 30 (LODR)-Scheme of Arrangement |
| Mon 26 Oct, 3:17 pm | Compliances-Reg. 54 – Asset Cover details |
| Mon 26 Oct, 3:14 pm | Board Meeting Outcome for Results For The Quarter And Half Year Ended 30Th September 2026 |
| Mon 26 Oct, 3:11 pm | Results For The Quarter And Half Year Ended 30Th September 2026 |
Q2 FY27 results at a glance
| ₹ crore | Q2 FY27 | Q2 FY26 | Change | Q1 FY27 | Change |
|---|---|---|---|---|---|
| Revenue from operations | 4,338 | 3,697 | +17.33% | 4,031 | +7.62% |
| Profit before tax | 929 | 624 | +48.89% | 769 | +20.75% |
| Net profit | 716 | 520 | +37.67% | 574 | +24.74% |
| Net profit as a share of revenue | 16.51% | 14.07% | – | 14.24% | – |
Mankind Pharma reported revenue from operations of ₹4,338 crore for Q2 FY27. The net profit of ₹716 crore represents a 37.67% increase compared to a year earlier. For the first 6 months of the fiscal year, the company recorded a net profit of ₹1,290 crore.
How Mankind Pharma compares with its sector
| Change today | |
|---|---|
| Mankind Pharma | +8.86% |
| Nifty Pharma | +1.90% |
| Nifty 50 | +0.29% |
| Gland Pharma | +4.82% |
| Divi’s Laboratories | +3.85% |
| Wockhardt | +3.61% |
| Piramal Pharma | +3.56% |
The Nifty Pharma index gained 1.90% during the session. Mankind Pharma gained 8.86%, while peer Gland Pharma rose 4.82% and Divi’s Laboratories gained 3.85%. The Nifty 50 index rose 0.29% during the same period.
Mankind Pharma share price: FAQs
What is the Mankind Pharma share price today?
₹2,516.80 at 12:44 IST on Tuesday 27 October 2026, up ₹204.80 or 8.86% from the previous close of ₹2,312.00.
What were Mankind Pharma’s Q2 FY27 results?
Consolidated revenue from operations of ₹4,338 crore (+17.33% year on year) and net profit of ₹716 crore (+37.67%), for the quarter ended 30 September 2026.
When did Mankind Pharma announce the results?
The board meeting outcome was filed on Mon 26 Oct, 3:14 pm IST.
How is the Pharma sector doing today?
Nifty Pharma was +1.90% at 12:44 IST on Tuesday 27 October 2026, against +8.86% for Mankind Pharma.
This article is for information only and is not investment advice. Prices are from the National Stock Exchange, filings from BSE announcements and results from the company’s reported figures. Calculations are by ThePip. Prices and figures move through the session; the time above says when these were read. Investments in securities are subject to market risks.